

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	ROSEN, Craig
				Group Art Unit	Unassigned 1647
				Examiner Name	Unassigned LANDSMAN
Sheet	1	of	9	Attorney Docket Number	PF112PID2

J0474 U.S. PTO
 10/023584
 12/21/01

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
BL	AA	5,633,147		Meissner <i>et al.</i>	05-27-1999
	AB	5,283,354		Lemischka	02-01-1994
	AC	5,240,848		Keck <i>et al.</i>	08-31-1993
	AD	5,234,908		Szabo <i>et al.</i>	08-10-1993
	AE	5,194,596		Tischer <i>et al.</i>	03-16-1993
	FO	5,861,301		Terman <i>et al.</i>	01-19-1999
	FQ	5,840,693		Eriksson <i>et al.</i>	11-24-1999
	BD	5,073,492		Chen <i>et al.</i>	12-17-1991
	BE	5,219,739		Tischer <i>et al.</i>	06-15-1993
	BF	5,326,695		Andersson <i>et al.</i>	07-05-1994
	BG	5,607,918		Eriksson <i>et al.</i>	03-04-1997
	BH	08/340011			11/1994
	BI	08/510133			08/1995
	BJ	08/585895			01/1996
	BK	08/601132			02/1996
	BL	08/671573			06/1996
	BM	00/003491			09/1993
✓	BN	08/554374			11/1995

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴ (if known)		
	AF		99/46364	Human Genome Sciences, Inc.	09-16-1999
	AG		98/33917	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	06-08-1998
✓	AH		98/07832	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. Oy	02-26-1998

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned		
		Filing Date	Concurrently Herewith		
		First Named Inventor	ROSEN, Craig		
		Group Art Unit	Unassigned- 1647		
		Examiner Name	Unassigned- LAndsmBAJ		
Sheet	2	of	9	Attorney Docket Number	PF112P1D2

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number ⁴ (if known)			
	AI		96/39515	Human Genome Sciences, Inc.	12-12-1996	
	AJ		96/05856	Human Genome Sciences, Inc.	02-29-1996	
	AK		95/24414	Human Genome Sciences, Inc.	09-14-1995	
	AL		95/19985	Human Genome Sciences, Inc.	07-27-1995	
	AM		92/14748	American Cyanamid Co.	09-03-1992	
	FR		94/403464	Human Genome Sciences, Inc.	01-31-1996	
	AU		99/21590	Merck & Co.	05-06-1999	
	AV		99/08522	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	02-25-1999	
	AW		98/56936	Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V.	12-17-1998	
	AX		98/49300	Collateral Therapeutics	11-05-1998	
	AY		98/39035	The Wistar Institute of Anatomy & Biology	09-11-1998	
	AZ		98/24811	Zymogenetics, Inc.	06-11-1998	
	BB		98/06844	Human Genome Sciences, Inc.	02-19-1998	
	BC		710696	Genentech, Inc.	09-30-1999	
	BO		0-476983	Bayne et al.	03-25-1992	
	BP		0-506477	Bayne et al.	09-30-1992	
	BQ		97/05250	University of Helsinki	02-13-1997	
	BR		97/09427	Genentech, Inc.	03-13-1997	
	BS		97/17442	Immunex Corporation	05-15-1997	

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	Concurrently Herewith
		First Named Inventor	ROSEN, Craig
		Group Art Unit	Unassigned - 1647
		Examiner Name	Unassigned - LANDSBERG
Sheet	3	of	9
		Attorney Docket Number	PF112P1D2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BL	BT	ACHEN <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci. (USA)</i> , 95(2): 548-553 (1998).	
	BU	ANDERSSON <i>et al.</i> , "Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF," <i>J. Biol. Chem.</i> , 267(16): 11260-11266 (1992).	
	BV	ALDERSON, R. F., Yourey, P. A., and Su, J. Y. (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. <i>Keystone Symposia, Ocular Cell and Molecular Biology</i> , 202. (Abstract provided)	
	BW	ANDERSSON W.F., "Human gene therapy," <i>Science</i> , 256:808-813 (1992).	
	BX	Aprelikova <i>et al.</i> , "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter," <i>Cancer Research</i> , 52:746-748 (1992).	
	BY	DIGNAM <i>et al.</i> , "Balbiani ring 3 in <i>chironomus tentans</i> encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," <i>Gene</i> 88:133-140 (1990).	
	BZ	FERRARA <i>et al.</i> , "Molecular and biological properties of the vascular endothelial growth factor family of proteins," <i>Endocrine Rev.</i> 13(1): 18-32 (1992).	
	CA	FINNERTY <i>et al.</i> , "Molecular cloning of murine FLT and FLT4," <i>Oncogene</i> 8(11): 2293-2298 (1993).	
	CB	HELDIN <i>et al.</i> , "Structure of platelet-derived growth factor: implications for functional properties," <i>Growth Factors</i> 8:245-252 (1993).	
	CC	EICHMANN <i>et al.</i> , "Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors," <i>Development</i> 125(4): 743-752 (1998).	
	CD	PAJUSOLA <i>et al.</i> , "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <i>Cancer Research</i> 52:5738-5743 (1992).	
	CE	LEUNG <i>et al.</i> , "Vascular endothelial growth factor is a secreted angiogenic mitogen," <i>Science</i> 246:1306-1309 (1989).	
	CF	BREIER <i>et al.</i> , "Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation," <i>Development</i> 114:521-532 (1992).	
	CG	BELL <i>et al.</i> , "Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization," <i>Nucl. Acids Res.</i> 14(21): 8427-8446 (1986).	
	CH	BERSE <i>et al.</i> , Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors," <i>Mol. Biol. Cell.</i> 3:211-220 (1992).	

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	Concurrently Herewith
		First Named Inventor	ROSEN, Craig
		Group Art Unit	Unassigned 1647
		Examiner Name	Unassigned L. ANDERSON
Sheet	4	of	9
		Attorney Docket Number	PF112P1D2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BC	CI	BETSHOLTZ <i>et al.</i> , "cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines," <i>Nature</i> 320:695-699 (1986).	
	CJ	CLAFFEY <i>et al.</i> , "Vascular endothelial growth factor," <i>J. Biol. Chem.</i> 267(23): 16317-16322 (1992).	
	CK	CORSON <i>et al.</i> , "Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end," <i>Genomics</i> 17:476-484 (1993).	
	CL	FERRARA <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cellular Biochemistry</i> 47:211-218 (1991).	
	CM	GEORGE <i>et al.</i> , "Current Methods in Sequence Comparison and Analysis," <i>Macromolecular Seq. and Syn. Selected Meth - Application</i> (Alan R. Liss), pp. 127-149 (1988).	
	CN	HU <i>et al.</i> , "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells," <i>FASEB J.</i> , 11:498-504 (1997).	
	CO	JOUKOV <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15(2): 290-298 (1996).	
	CP	JOUKOV <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO J.</i> 16(13): 3898-3911 (1997).	
	CQ	KAIPAINEN <i>et al.</i> , "The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells," <i>J. Exp. Med.</i> 178:2077-2088 (1993).	
	CR	KECK <i>et al.</i> , "Vascular permeability factor, an endothelial cell mitogen related to PDGF," <i>Science</i> 246: 1309 (1989).	
	CS	KINGSLEY, D., "The TGF- β superfamily: new members, new receptors, and new genetic tests of function in different organisms," <i>Genes & Development</i> 8: 133-146 (1994).	
	CT	KUKK <i>et al.</i> , "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," <i>Development</i> 122: 3829-37 (1996).	
	CU	LEE <i>et al.</i> , "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4," <i>Proc. Natl. Acad. Sci. (USA)</i> , 93:1988-1992 (1996).	
	CV	MAGLIONE <i>et al.</i> , "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-931 (1993).	

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned		
		Filing Date	Concurrently Herewith		
		First Named Inventor	ROSEN, Craig		
		Group Art Unit	Unassigned- 1647		
		Examiner Name	Unassigned- LANDSMAN		
Sheet	5	of	9	Attorney Docket Number	PF112PID2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AL	CW	MAGLIONE <i>et al.</i> , "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9267-9271 (1991).	
	CX	MASSAGUE, J., "The transforming growth factor-beta family," <i>Annu. Rev. Cell Biol.</i> 6:597-641 (1990).	
	CY	MATTHEWS <i>et al.</i> , "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9026-9030 (1991).	
	CZ	MILLAUER <i>et al.</i> , "High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993).	
	DA	MILLAUER <i>et al.</i> , "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," <i>Nature</i> 367:576-579 (1994).	
	DB	OLTVAI <i>et al.</i> , "Bcl-2 heterodimerizes <i>in vivo</i> with a conserved homolog, bax, that accelerates programmed cell death," <i>Cell</i> 74:609-619 (1993).	
	DC	PAULSSON <i>et al.</i> , "The balbani ring 3 gene in <i>chironomus tentans</i> has a diverged repetitive structure split by many introns," <i>J. Mol. Biol.</i> 211:331-349 (1990).	
	DD	PAJUSOLA <i>et al.</i> , "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <i>Oncogene</i> 8:2931-2937 (1993).	
	DE	TISCHER <i>et al.</i> , "Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family," <i>Biochem. & Biophys. Res. Comms.</i> 165(3): 1198-1206 (1989).	
	DF	TANAKA <i>et al.</i> , "DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes," <i>Mol. Cell Biol.</i> 7(5): 1978-1983 (1987).	
	DG	TERMAN <i>et al.</i> , "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> 6:1677-1683 (1991).	
	DH	TERMAN <i>et al.</i> , "Identification of the kdr-tyrosine kinase as a receptor for vascular endothelial cell growth factor," <i>Biochem. Biophys. Res. Commun.</i> 187(3): 1579-1586 (1992).	
	DI	TSUJIMOTO <i>et al.</i> , "Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci. (USA)</i> , 83:5214-5218 (1986).	
	DJ	TISCHER <i>et al.</i> , "The Human Gene for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> 266(18): 11947-11954 (1991).	
	DK	FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> 2:93-98 (1992).	

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	Concurrently Herewith
		First Named Inventor	ROSEN, Craig
		Group Art Unit	Unassigned 1647
		Examiner Name	Unassigned LANDSMAN
Sheet	6	of	9
		Attorney Docket Number	PF112P1D2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
ML	DL	WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> 306(2): 129-136 (1993).	
	DM	HOCKEL <i>et al.</i> , "Therapeutic angiogenesis," <i>Arch. Surg.</i> 128:423-429 (1993).	
	DN	GUZMAN <i>et al.</i> "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> 73:1202-1207 (1993).	
	DO	BELLOMO <i>et al.</i> , "Mice Lacking the Vascular Endothelial Growth Factor- β Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> 89(2): e29-e35 (2000).	
	DP	COCKERILL <i>et al.</i> , "Angiogenesis: Models and Modulators" <i>Infl. Rev. Cytology</i> 159:113-160 (1995).	
	DQ	GAMBLE <i>et al.</i> , "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> 121(4): 931-943 (1993).	
	DR	GOLDSPIEL <i>et al.</i> , "Human Gene Therapy," <i>Clinical Pharmacy</i> 12: 488-505 (1993).	
	DS	GRIMMOND <i>et al.</i> , "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> 6:124-131 (1996).	
	DT	HYDE <i>et al.</i> , "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> 362: 250-255 (1993).	
	DU	KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993).	
	DV	KOLODKA <i>et al.</i> , "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> 19(5): 491-497 (1993).	
	DW	LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129.	
ML	DX	SHIBUYA <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 519-524 (1990).	
	DY	SILINS <i>et al.</i> , "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> 230: 413-418 (1997).	
	DZ	STEWART <i>et al.</i> , "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> 11: 335-341 (1993).	
	EA	TOWNSON <i>et al.</i> , "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comms.</i> 220: 922-928 (1996).	
	EB	WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204: 289-300.	

Examiner Signature		Date Considered	10-28-03
--------------------	--	-----------------	----------

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned		
		Filing Date	Concurrently Herewith		
		First Named Inventor	ROSEN, Craig		
		Group Art Unit	Unassigned 1647		
		Examiner Name	Unassigned LADMAN		
Sheet	7	of	9	Attorney Docket Number	PF112PID2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BL	EC	YOUREY, P. A., Gohari, S., Su, J. Y. and Alderson, R. F. (2000) Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells. J. Neuroscience, 20: 6781 - 6788.	
	ED	YOUREY, P. A., Gohari, S., and Alderson, R. F., (1999) Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro. Soc. Cell Biology, 227. (Abstract provided)	
	EF	GenBank Accession No. X68203, APRELIKOVA <i>et al.</i> , "H.sapiens mRNA for FLT4, class III receptor tyrosine kinase," November 30, 1993.	
	EG	GenBank Accession No. M95200, CLAFFEY <i>et al.</i> , "Mouse vascular endothelial growth factor mRNA, complete cds," April 27, 1993.	
	EH	GenBank Accession No. M24160, DIGNAM <i>et al.</i> , "C.tentans 185-kd secretory protein (sp185) mRNA, partial cds, clone pCt185," April 26, 1993.	
	EI	GenBank Accession No. M24276, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.1," April 26, 1993.	
	EJ	GenBank Accession No. M24277, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.2," April 26, 1993.	
	EK	GenBank Accession No. D88689, FINNERTY <i>et al.</i> , "Mus musculus mRNA for flt-1, complete cds," April 14, 2000.	
	EL	GenBank Accession No. L07296, FINNERTY <i>et al.</i> , "Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds," August 9, 1993.	
	EM	GenBank Accession No. X54936, MAGLIONE <i>et al.</i> , "H.sapiens mRNA for placenta growth factor (PlGF)," November 12, 1991.	
	EN	GenBank Accession No. S57152, MAGLIONE <i>et al.</i> , "Homo sapiens placenta growth factor 2 (PlGF-2) gene, partial cds," March 5, 2001.	
	EO	GenBank Accession No. X59397, MATTHEWS <i>et al.</i> , "Mouse Flk-1 mRNA for a tyrosine kinase receptor," November 6, 1991.	
	EP	GenBank Accession No. X52263, PAULSSON <i>et al.</i> , "C.tentans balbiani ring 3 (BR3) gene," December 18, 1992.	
	EQ	GenBank Accession No. M63971, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 1," August, 1993.	
	ER	GenBank Accession No. M63972, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 2," August 3, 1993.	
	ES	GenBank Accession No. M63973, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 3," August 3, 1993.	
	ET	GenBank Accession No. M63974, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 4," August 3, 1993.	

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned		
		Filing Date	Concurrently Herewith		
		First Named Inventor	ROSEN, Craig		
		Group Art Unit	Unassigned 1647		
		Examiner Name	Unassigned LANDSMAN		
Sheet	8	of	9	Attorney Docket Number	PF112PID2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL	EU	GenBank Accession No. M63975, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 5," August 3, 1993.	
	EV	GenBank Accession No. M63976, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 6," August 3, 1993.	
	EW	GenBank Accession No. M63977, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 7," August 3, 1993.	
	EX	GenBank Accession No. M63978, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 8," August 3, 1993.	
	EY	GenBank Accession No. M27281, KECK <i>et al.</i> , "Human vascular permeability factor mRNA, complete cds," August 3, 1993.	
	EZ	GenBank Accession No. X04571, BELL <i>et al.</i> , "Human mRNA for kidney epidermal growth factor (EGF) precursor," March 21, 1995.	
	FA	GenBank Accession No. X63556, CORSON <i>et al.</i> , "H. sapiens mRNA for fibrillin," February 17, 1997.	
	FB	GenBank Accession No. L19896, CORSON <i>et al.</i> , "Human fibrillin (FBN1) gene, 5'end including alternative exons A, B, and C, and exon M," November 8, 1994.	
	FC	GenBank Accession No. L04947, TERMAN <i>et al.</i> , "Homo sapiens (clones BT3.081.8, BT3.129.5 and BT4.169)," January 6, 1995.	
	FD	GenBank Accession No. M16237, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 2," January 13, 1995.	
	FE	GenBank Accession No. M16243, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 3," January 13, 1995.	
	FF	GenBank Accession No. M16244, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 4, January 13, 1995.	
	FG	GenBank Accession No. M16245, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 5," January 13, 1995.	
	FH	GenBank Accession No. K03212, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 6," January 13, 1995.	
	FI	GenBank Accession No. K03213, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 7," January 13, 1995.	
	FJ	GenBank Accession No. K03214, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 8," January 13, 1995.	
	FK	GenBank Accession No. K03215, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 9," January 13, 1995.	
↓	FL	GenBank Accession No. K03216, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 10, January 13, 1995.	

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	ROSEN, Craig
				Group Art Unit	Unassigned 1647
				Examiner Name	Unassigned Landman
Sheet	9	of	9	Attorney Docket Number	PF112P1D2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AL	FM	GenBank Accession No. K03217, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 11," January 13, 1995.	
	FN	GenBank Accession No. K03218, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 12," January 13, 1995.	
	FO	GenBank Accession No. M13994, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds," October 31, 1994.	
	FP	GenBank Accession No. M13995, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-3-beta protein, complete cds," October 31, 1994.	
	FQ	GenBank Accession No. L22473, OLTVAI <i>et al.</i> , "Human Bax alpha mRNA, complete cds," December 15, 1993.	
	FR	GenBank Accession No. L22474, OLTVAI <i>et al.</i> , "Human Bax beta mRNA, complete cds," December 13, 1993.	
	FS	GenBank Accession No. AJ000185, ACHEN <i>et al.</i> , "Homo Sapiens mRNA for vascular endothelial growth factor-D," February 11, 1998.	
	FT	International Search Report, Application No. PCT/US99/05021	
	FU	International Search Report, Application No. PCT/US94/05291	

Examiner Signature		Date Considered	10/28/03
--------------------	--	-----------------	----------

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/023,584
		Filing Date	December 21, 2001
		First Named Inventor	Rosen, et al.
		Group Art Unit	1647
		Examiner Name	<i>Landsman</i> Unassigned
Sheet	1	of	1
		Attorney Docket Number	PF112P1D2

TECH CENTER 1600/2900

MAR 14 2002

RECEIVED

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)	
<i>ML</i>	FV	EP	0476983	A1	Merck & Co., Inc.

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	FW	International Search Report, Application No. PCT/US01/24658 mailed on Dec 12, 2001

Examiner Signature	<i>Rosen</i>	Date Considered	10/28/03
-----------------------	--------------	--------------------	----------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.